Metabolomic Profiles in Childhood and Adolescence Are Associated with Fetal Overnutrition

Ellen C. Francis 1,*, Katerina Kechris 2, Catherine C. Cohen 1,3,*, Gregory Michelotti 4, Dana Dabelea 1,3,5, and Wei Perng 1,5

1 Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA; catherine.cioffi@cuanschutz.edu (C.C.C.); dana.dabelea@cuanschutz.edu (D.D.); wei.perng@cuanschutz.edu (W.P.)
2 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; Katerina.Kechris@cuanschutz.edu
3 Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
4 Metabolon, Inc., Morrisville, NC 27560, USA; GMichelotti@metabolon.com
5 Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA
* Correspondence: ellen.francis@cuanschutz.edu

Abstract: Fetal overnutrition predisposes offspring to increased metabolic risk. The current study used metabolomics to assess sustained differences in serum metabolites across childhood and adolescence among youth exposed to three typologies of fetal overnutrition: maternal obesity only, gestational diabetes mellitus (GDM) only, and obesity + GDM. We included youth exposed in utero to obesity only (BMI ≥ 30; n = 66), GDM only (n = 56), obesity + GDM (n = 25), or unexposed (n = 297), with untargeted metabolomics measured at ages 10 and 16 years. We used linear mixed models to identify metabolites across both time-points associated with exposure to any overnutrition, using a false-discovery-rate correction (FDR) <0.20. These metabolites were included in a principal component analysis (PCA) to generate profiles and assess metabolite profile differences with respect to overnutrition typology (adjusted for prenatal smoking, offspring age, sex, and race/ethnicity). Fetal overnutrition was associated with 52 metabolites. PCA yielded four factors accounting for 17–27% of the variance, depending on age of measurement. We observed differences in three factor patterns with respect to overnutrition typology: sphingomyelin-mannose (8–13% variance), skeletal muscle metabolism (6–10% variance), and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF; 3–4% variance). The sphingomyelin-mannose factor score was higher among offspring exposed to obesity vs. GDM. Exposure to obesity + GDM (vs. GDM or obesity only) was associated with higher skeletal muscle metabolism and CMPF scores. Fetal overnutrition is associated with metabolic changes in the offspring, but differences between typologies of overnutrition account for a small amount of variation in the metabolome, suggesting there is likely greater pathophysiological overlap than difference.

Keywords: pregnancy; obesity; gestational diabetes mellitus; metabolomics; childhood

1. Introduction

Maternal obesity and Gestational Diabetes Mellitus (GDM) are interrelated metabolic conditions leading to fetal overnutrition, a term that refers to fetal exposure to excess maternal fuels including but not limited to glucose, amino acids, and lipids [1]. Although these conditions are interrelated, GDM with or without maternal obesity may represent different metabolic entities [2], and thus may have implications for in utero programming. For instance, large epidemiological studies have demonstrated independent and exposure-specific effects of GDM or obesity in relation to offspring outcomes (e.g., obesity vs. fat mass % vs. cardiovascular disease vs. diabetes) [1,3–6]. In 597 adult offspring of Danish women...
with GDM, there was an eight-fold increased risk of pre-diabetes or diabetes [3]. Among over 4500 mother–offspring pairs from an international multicenter cohort, GDM has been associated with a 5% risk difference in offspring obesity during adolescence, even after accounting for maternal body mass index (BMI) [4]. In a Swedish population-based cohort, age-adjusted cardiovascular disease rates in offspring increased linearly with maternal BMI status in pregnancy [5].

Recent data indicate that there are overlapping as well as distinct changes in the metabolome of offspring [7–9], depending on exposure to these fetal overnutrition typologies (i.e., obesity or GDM). These studies have used metabolomics in offspring to capture the consequences of exposure to maternal obesity or GDM. For instance, maternal overweight/obesity, but not glucose tolerance status, has been associated with increased branched-chain amino acids (BCAAs) in cord blood [7,10,11]. Maternal BMI and glucose levels have been correlated with an offspring metabolite profile characterized by phospho- and sphingo-lipids in childhood (5–7 years of age) [8]. Similarly, we have found that exposure to GDM was associated with an offspring metabolite profile characterized by higher phospholipids during childhood and adolescences [9]. However, this association was attenuated after accounting for maternal pre-pregnancy BMI, which may represent an overlapping biological pathway [9]. This biological overlap is likely related to the effects of excess adiposity and insulin resistance, leading to increased glucose levels during pregnancy [12]. Nevertheless, there may also be distinct biochemical/metabolic pathways affected by exposure to maternal obesity and/or GDM. A more nuanced characterization of such differences with respect to type of fetal overnutrition—i.e., exposure to maternal obesity only, GDM only, or both—may elucidate differences in metabolic processes linking these conditions to long-term offspring health.

The objective of this hypothesis-generating analysis was to extend current knowledge on the relationship between fetal overnutrition and offspring metabolic health by leveraging repeated untargeted metabolomics data in offspring across 6 years of follow-up. We aimed to: (1) identify a set of metabolites associated with any type of fetal overnutrition; (2) identify differences in offspring metabolite profiles with respect to maternal obesity only, GDM only, or both, thereby shedding light on distinct and shared pathways, and (3) assess the correlation of offspring metabolite profiles with conventional indicators of metabolic health to aid in interpretation of the metabolite profiles identified.

2. Results

2.1. Characteristics

The mean (±SD) age of participants at the childhood visit was 10.4 ± 1.5 years (range, 6.0–13.9 years), and at the adolescent visit, it was 16.7 ± 1.2 years (range, 12.6–19.6 years). Approximately half the participants were female, and 33% were exposed to any fetal overnutrition (obesity or GDM). Maternal and child characteristics by fetal overnutrition typology are presented in Table 1. The frequency of women who smoked during pregnancy differed across typology: of the women with obesity and GDM, 20.0% reported smoking, whereas the percentage of smokers among women with GDM only, obesity only, or neither was 17.9%, 6.1%, and 7.2%, respectively. There was a higher percentage of Hispanic offspring among women with GDM only or obesity and GDM (57.6%), and a higher percentage of non-Hispanic White offspring among women with GDM only or obesity and GDM (71.4% and 52.0%). As expected, offspring of women with obesity and GDM had a higher birthweight-for-gestational-age z-score. At each research visit, offspring of women with either obesity or GDM tended to be younger. Offspring of women with obesity only had the highest mean BMI.
Table 1. Bivariate associations of fetal overnutrition typologies with participant characteristics.

| Maternal Characteristics | Overnutrition Typology | p ¹ |
|--------------------------|------------------------|-----|
|                          | No GDM or Obesity      | Obese Only | GDM Only | GDM & Obesity |
| Pre-pregnancy BMI (kg/m²) | 23.2 ± 3.1             | 35.0 ± 5.3 | 24.0 ± 3.4 | 35.1 ± 4.1 |
| Education level          | <High school           | 3.1 (9)    | 6.1 (4)    | 5.4 (3)    |
|                          | High school or some college | 44.4 (130) | 62.1 (41) | 46.4 (26) |
| Associates degree or higher | 52.6 (154)             | 31.8 (21)  | 48.2 (27)  | 40.0 (10)  |
| Smoked during pregnancy  | 7.2 (21)               | 6.1 (4)    | 17.9 (10)  | 20.0 (5)   |
| Offspring characteristics at birth |                   |   |
| Female                   | 48.8 (143)             | 47.0 (31)  | 46.4 (26)  | 28.0 (7)   |
| Race/ethnicity           | Non-Hispanic White     | 42.3 (124) | 18.2 (12)  | 71.4 (40)  |
|                          | Hispanic               | 44.0 (129) | 57.6 (38)  | 21.4 (12)  |
|                          | Non-Hispanic Black     | 7.2 (21)   | 21.2 (14)  | 3.6 (2)    |
|                          | Non-Hispanic Other     | 6.5 (19)   | 3.0 (2)    | 3.6 (2)    |
| Birthweight for gestational age z-score ² |                   |   |
|                          | −0.4 ± 0.9             | −0.3 ± 1.0 | −0.1 ± 1.0 | 0.0 ± 0.9  | 0.02 |
| Childhood visit          | Age, years             | 10.7 ± 1.4 | 10.5 ± 1.4 | 9.5 ± 1.8  |
|                          | BMI (kg/m²)            | 18.6 ± 4.0 | 21.1 ± 5.5 | 18.1 ± 4.2 |
|                          | BMI z-score            | 0.2 ± 1.2  | 0.9 ± 1.1  | 0.1 ± 1.4  |
|                          | Kilocalories           | 1791.5 ± 565.3 | 1819.8 ± 581.1 | 1773.0 ± 495.5 | 1727.4 ± 415.2 | 0.90 |
|                          | Energy expenditure     | 68.4 ± 11.3 | 65.15 ± 9.41 | 66.04 ± 9.39 | 65.64 ± 11.91 | 0.09 |
| Adolescent visit         | Age, years             | 16.7 ± 1.1 | 16.4 ± 1.3 | 15.8 ± 1.1 |
|                          | BMI (kg/m²)            | 22.7 ± 4.8 | 28.0 ± 7.1 | 22.6 ± 4.6 |
|                          | BMI z-score ³          | 0.2 ± 1.1  | 1.2 ± 1.0  | 0.4 ± 1.1  |
|                          | Kilocalories           | 1672.5 ± 717.0 | 1599.4 ± 762.3 | 1730.2 ± 887.6 | 1660.7 ± 577.5 | 0.88 |
|                          | Energy expenditure     | 70.5 ± 16.1 | 66.87 ± 11.89 | 67.8 ± 13.5 | 78.25 ± 20.12 | 0.05 |

¹ ANOVA for continuous variables; Pearson chi-squared test for categorical variables. ² Birthweight for gestational age z-score based on U.S. national reference [13]. ³ Age- and sex-specific z scores according to the WHO Growth Reference for children aged 5–19 years [14]. Abbreviations: BMI, Body Mass Index; GDM, Gestational Diabetes Mellitus.

2.2. Identification of Metabolites in Offspring Associated with Any Fetal Overnutrition

The metabolome-wide association study (MWAS) yielded 52 metabolites across childhood and adolescence that were significantly associated with exposure to any fetal overnutrition (obesity or GDM) versus no exposure to overnutrition (false-discovery-rate [FDR] p-value < 0.20) (Table 2). These metabolites were predominately from peptide, amino acid, and lipid super classes.

Table 2. Metabolites in fasting serum of 440 youth in the Exploring Perinatal Outcomes among Children (EPOCH) cohort across 6 years of follow-up (childhood–adolescences) that differed with respect to exposure to any fetal overnutrition (OB and/or GDM vs. neither).

| Compound              | Superclass   | Subclass                           | p-Value | FDR p-Value |
|-----------------------|--------------|------------------------------------|---------|-------------|
| Tyrosine              | Amino Acid   | Tyrosine Metabolism                | 0.001   | 0.119       |
| Homoarginine          | Amino Acid   | Urea cycle; Arginine and Proline Metabolism | 0.002   | 0.144       |
| 2-hydroxy-3-methylvalerate | Amino Acid | Leucine, Isoleucine and Valine Metabolism | 0.004   | 0.144       |
| 3-methyl-2-oxobutyrate | Amino Acid | Leucine, Isoleucine and Valine Metabolism | 0.002   | 0.144       |
| 2-amino adipate       | Amino Acid   | Lysine Metabolism                  | 0.007   | 0.154       |
| Glycine               | Amino Acid   | Glycine, Serine and Threonine Metabolism | 0.007   | 0.154       |
| N-acetylglycine       | Amino Acid   | Glycine, Serine and Threonine Metabolism | 0.008   | 0.158       |
Table 2. Cont.

| Compound                                      | Superclass                  | Subclass                                      | p-Value | FDR  
|-----------------------------------------------|-----------------------------|-----------------------------------------------|---------|------
| Methionine sulfoxide                          | Amino Acid                  | Methionine, Cysteine, SAM, Taurine             | 0.010   | 0.167 |
| Alpha-hydroxyisocaproate                      | Amino Acid                  | Leucine, Isoleucine and Valine Metabolism      | 0.014   | 0.190 |
| Mannitol/sorbitol                             | Carbohydrate                | Fructose, Mannose and Galactose Metabolism     | 0.003   | 0.144 |
| Glucuronate                                   | Carbohydrate                | Aminosugar Metabolism                         | 0.004   | 0.144 |
| Mannose                                       | Carbohydrate                | Fructose, Mannose and Galactose Metabolism     | 0.005   | 0.144 |
| Farnothenate                                  | Co-factors, Vitamins        | Farnothenate and CoA Metabolism               | 0.001   | 0.119 |
| Alpha-ketoglutarate                           | Energy                      | TCA Cycle                                     | 0.001   | 0.119 |
| Citrate                                       | Energy                      | TCA Cycle                                     | 0.004   | 0.144 |
| Malate                                        | Energy                      | TCA Cycle                                     | 0.006   | 0.144 |
| Succinate                                     | Energy                      | TCA Cycle                                     | 0.012   | 0.181 |
| 12-HETE                                      | Lipid                       | Eicosanoid                                    | 0.000   | 0.119 |
| 13-HODE + 9-HODE                             | Lipid                       | Fatty Acid, Mono-hydroxy                     | 0.002   | 0.119 |
| Hydroxy-CMPF 1                                | Lipid                       | Fatty Acid, Dicarboxylate                    | 0.005   | 0.144 |
| Choline                                       | Lipid                       | Phospholipid Metabolism                      | 0.005   | 0.144 |
| 3-hydroxybutyroylglycine 1                    | Lipid                       | Fatty Acid Metabolism (Acyl Glycine)         | 0.005   | 0.144 |
| 7-alpha-hydroxy-3-oxo-4-cholestenoate (7-Hoca) | Lipid                       | Sterol                                        | 0.006   | 0.144 |
| Palmitoyl-arachidonoyl-glycerol (16:0/20:4) 2 | Lipid                       | Diacylglycerol                                | 0.006   | 0.144 |
| N-oleoylserine                                | Lipid                       | Endocannabinoid                               | 0.007   | 0.154 |
| 1-linoleoyl-GPA (18:2) 1                      | Lipid                       | Lysosphospholipid                            | 0.009   | 0.158 |
| Hexanoyl carnitine (C6)                       | Lipid                       | Fatty Acid Metabolism (Acyl Carnitine)        | 0.009   | 0.161 |
| 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) | Lipid                       | Fatty Acid, Dicarboxylate                    | 0.012   | 0.180 |
| Glycosyl-N-palmitoyl-sphingosine (d18:1/16:0) | Lipid                       | Hexosylceramides (HCER)                      | 0.012   | 0.181 |
| 1-(1-enyl-palmitoyl)-GPC (P-16:0) 1            | Lipid                       | Lyso-plasmalogen                             | 0.013   | 0.188 |
| Sphingomyelin (d18:2/14:0, d18:1/14:1) 1       | Lipid                       | Sphingomyelins                                | 0.014   | 0.190 |
| Dodecadienoate (12:2) 1                       | Lipid                       | Fatty Acid, Dicarboxylate                    | 0.016   | 0.193 |
| 1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1) 1 | Lipid                       | Plasmalogen                                   | 0.016   | 0.193 |
| Sphingomyelin (d18:0/18:0, d19:0/17:0) 1       | Lipid                       | Dihydro-sphingomyelins                        | 0.016   | 0.193 |
| Dihy droo roto te                             | Nucleotide                  | Pyrimidine Metabolism, Orotate contain.        | 0.002   | 0.119 |
| Urate                                         | Nucleotide                  | Purine Metabolism, (Hypo)Xanthine/Inosine     | 0.009   | 0.158 |
| N1-methyladenosine                            | Nucleotide                  | Purine Metabolism, Adenine contain.           | 0.010   | 0.167 |
| Guanosine                                     | Nucleotide                  | Purine Metabolism, Guanine contain.           | 0.013   | 0.189 |
| Fibrinopeptide A, des-ala(1) 1                | Peptide                     | Fibrinogen Cleavage Peptide                  | 0.001   | 0.119 |
| Gamma-glutamyIglutamate                       | Peptide                     | Gamma-glutamyl Amino Acid                     | 0.004   | 0.144 |
| Gamma-glutamyIcitulline 1                    | Peptide                     | Gamma-glutamyl Amino Acid                     | 0.004   | 0.144 |
| Gamma-glutamyI-alpha-lysine                  | Peptide                     | Gamma-glutamyl Amino Acid                     | 0.004   | 0.144 |
| Glycyvaline                                   | Peptide                     | Dipeptide                                    | 0.008   | 0.158 |
| Gamma-glutamyIthreonine                      | Peptide                     | Gamma-glutamyl Amino Acid                     | 0.009   | 0.163 |
| Gamma-glutamyI-2-amino butyrate               | Peptide                     | Gamma-glutamyl Amino Acid                     | 0.009   | 0.163 |
| Gamma-glutamyIglycine                         | Peptide                     | Gamma-glutamyl Amino Acid                     | 0.014   | 0.190 |
| Phenylalanaylglycine                          | Peptide                     | Dipeptide                                    | 0.015   | 0.193 |
| Sulfate of piperine metabolite Cl6H19N03 (2) 1 | Xenobiotics                | Food Component/Plant                         | 0.000   | 0.119 |
| Sulfate of piperine metabolite Cl6H19N03 (3) 1 | Xenobiotics                | Food Component/Plant                         | 0.001   | 0.119 |
| Quinate                                       | Xenobiotics                | Food Component/Plant                         | 0.004   | 0.144 |
| Piperine                                      | Xenobiotics                | Food Component/Plant                         | 0.004   | 0.144 |
| Perfluorooctanesulfonate (PFOS)               | Xenobiotics                | Chemical                                     | 0.011   | 0.174 |

Abbreviations: OB, pre-pregnancy obesity; GDM, Gestational Diabetes Mellitus. Adjusted for maternal smoking in pregnancy, child sex, race, and age at visit. Tier 2 identification in which no commercially available authentic standards could be found, but annotated based on accurate mass, spectral and chromatographic similarity to tier 1-identified compounds.

2.3. Associations between Fetal Overnutrition Typologies and Offspring Metabolite Profiles

We implemented the PCA on the 52 metabolites identified from the MWAS and selected six factors to retain at each visit based on the break in Scree plot and shown in Table 3. Following qualitative assessment of the top loading metabolites, we noted consistency in factor composition for four factors across the two visits: γ-glutamyl-peptide factor, sphingomyelin-mannose factor, skeletal muscle metabolism factor, and the 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) factor. The first factor, which accounts for the most variation in metabolites associated with fetal overnutrition (i.e., 44% variance at the childhood visit, 20% at the adolescent visit), was driven by compounds in the γ-glutamyl-peptide amino acid subclass (top three metabolites were: γ-glutamylglutamate, γ-glutamyl-α-lysine, γ-glutamylglycine) was well as some phospholipids and fatty acids.
Table 3. Metabolite factors and factor loadings of the top metabolites at the childhood and adolescent visits.

| Factor Loading | Childhood Visit | Adolescent Visit | Compound | Superclass | Subclass                      |
|---------------|-----------------|-----------------|----------|------------|--------------------------------|
| Factor label: γ-glutamyl | Factor 1 (44% variance) | Factor 1 (20% variance) | Gamma-glutamylglutamate | Peptide | Gamma-glutamyl Amino Acid |
|               | 0.81            | 0.83            | Gamma-glutamyl-alpha-lysine | Peptide | Gamma-glutamyl Amino Acid |
|               | 0.77            | 0.81            | Gamma-glutamylglycine       | Peptide | Gamma-glutamyl Amino Acid |
|               | 0.72            | 0.69            | Methionine sulfoxide        | Amino Acid | Methionine, Cysteine, SAM, Taurine Metabolism |
|               | 0.66            | 0.68            | Glycylvaline                | Peptide | Dipeptide |
|               | 0.66            | 0.68            | 1-linoleoyl-GPA (18:2)      | Lipid   | Lysophospholipid |
|               | 0.61            | <0.40           | 13-HODE + 9-HODE            | Lipid   | Fatty Acid, Monohydroxy |
|               | 0.61            | 0.65            | Choline                     | Lipid   | Phospholipid Metabolism |
|               | <0.40           | 0.62            | Gamma-glutamylthreonine     | Peptide | Gamma-glutamyl Amino Acid |
| Factor label: Sphingomyelin-mannose | Factor 3 a (8% variance) | Factor 2 a (13% variance) | Sphingomyelin (d18:2/14:0, d18:1/14:1) | Lipid | Sphingomyelins |
|               | 0.61            | 0.58            | Sphingomyelin (d18:0/18:0, d19:0/17:0) | Lipid | Dihydrosphingomyelins |
|               | 0.59            | 0.64            | Mannose                     | Carbohydrate | Fructose, Mannose and Galactose Metabolism |
|               | 0.54            | 0.59            | Homoarginine                | Amino Acid | Urea cycle, Arginine and Proline Metabolism |
|               | 0.52            | 0.58            | N1-methyladenosine          | Nucleotide | Purine Metabolism, Adenine containing |
|               | 0.45            | 0.50            | N1-methyldenosine           | Nucleotide | |
| Factor label: Skeletal muscle metabolism | Factor 4 (6% variance) | Factor 4 (10% variance) | Alpha-hydroxyisocaproate    | Amino Acid | Leucine, Isoleucine and Valine Metabolism |
|               | 0.63            | 0.76            | 2-hydroxy-3-methylvalerate  | Amino Acid | Leucine, Isoleucine and Valine Metabolism |
|               | 0.49            | 0.62            | Malate                      | Energy  | TCA Cycle |
|               | 0.40            | 0.51            | Malate                      | Energy  | Purine Metabolism, (Hypo)Xanthine/Inosine TCA Cycle |
|               | 0.40            | 0.51            | Urate                       | Nucleotide | |
|               | <0.40           | <0.40           | Citrate                     | Nucleotide | |
|               | <0.40           | 0.41            | 7-alpha-hydroxy-3-oxo-4-cholestenoate (7-Hoca) | Lipid | Sterol |
| Factor label: 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) | Factor 6 (3% variance) | Factor 6 (4% variance) | 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) | Lipid | Fatty Acid, Dicarboxylate |
|               | 0.71            | 0.90            | Sulfate of piperine metabolite C16H19NO3 (2) | Xenobiotics | Food Component/Plant |
|               | 0.58            | 0.94            | Sulfate of piperine metabolite C16H19NO3 (3) | Xenobiotics | Food Component/Plant |
|               | 0.56            | 0.93            | Piperine                     | Xenobiotics | Food Component/Plant |
|               | 0.51            | 0.85            | 2-aminoadipate              | Xenobiotics | Food Component/Plant |
|               | 0.50            | <0.40           | 2-hydroxy-3-methylvalerate  | Amino Acid | Leucine, Isoleucine and Valine Metabolism |
|               | 0.45            | <0.40           | 2-hydroxy-3-methylvalerate  | Amino Acid | Leucine, Isoleucine and Valine Metabolism |
| Factor 5 (4% variance) | Factor 5 (4% variance) | Factor 5 (4% variance) | Sulfate of piperine metabolite C16H19NO3 (2) | Xenobiotics | Food Component/Plant |
|               | 0.50            | <0.40           | Sulfate of piperine metabolite C16H19NO3 (3) | Xenobiotics | Food Component/Plant |
|               | 0.49            | <0.40           | Piperine                     | Xenobiotics | Food Component/Plant |
|               | 0.43            | <0.40           | Dodecadienoate (12:2) *     | Lipid | Fatty Acid, Dicarboxylate |
Table 3. Cont.

| Childhood Visit | Adolescent Visit | Compound                  | Superclass                        | Subclass                                           |
|-----------------|------------------|---------------------------|-----------------------------------|---------------------------------------------------|
| <0.40           | 0.53             | 3-hydroxybutyrylglycine * | Lipid                             | Fatty Acid Metabolism (Acyl Glycine)              |
| <0.40           | 0.44             | Hexanoylcarnitine (C6)    | Lipid                             | Fatty Acid Metabolism (Acyl Carnitine)            |
| <0.40           | 0.57             | N-acetylglycine           | Amino Acid                        | Glycine, Serine and Threonine Metabolism          |
| <0.40           | 0.45             | Glycine                   | Amino Acid                        | Glycine, Serine and Threonine Metabolism          |

**Note:** Labeled factors are of interest due to similarity in non-xenobiotic composition at both the childhood and adolescent visits. * Factor number differed across research visits. * Tier 2 identification in which no commercially available authentic standards could be found, but annotated based on accurate mass, spectral and chromatographic similarity to tier 1-identified compounds.

Although the γ-glutamyl-peptide factor score was lower among offspring of women with obesity only vs. GDM only (Figure 1), covariate adjustment attenuated the difference, and the confidence intervals included the null (Table 4).

![Figure 1](image-url)

**Figure 1.** Unadjusted associations (β [95% CI]) of fetal overnutrition (obesity and GDM, obesity only, and GDM only) with metabolite factor scores across 6 years of follow-up among 444 youth in the EPOCH cohort. (A) Longitudinal association fetal overnutrition typology and γ-glutamyl factor scores: offspring of women with obesity only had significantly lower factor scores compared to offspring of women with GDM only. (B) Longitudinal association fetal overnutrition typology and sphingomyelin-mannose factor scores: offspring of women with obesity only had significantly higher factor scores compared to offspring of women with GDM only. (C) Longitudinal association fetal overnutrition typology and skeletal muscle metabolism factor scores: offspring of women with obesity and GDM had significantly higher factor scores compared to offspring of women with GDM only, and offspring of women with obesity only. (D) Longitudinal association fetal overnutrition typology and CMPF factor scores: offspring of women with obesity and GDM had significantly higher factor scores compared to offspring of women with GDM only. Offspring of women with obesity only had significantly higher factor scores compared to women with GDM only. Abbreviations: CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid; GDM, Gestational Diabetes Mellitus; Sphingomyelin, SM; OB, pre-pregnancy obesity. * p < 0.05.
Table 4. Longitudinal associations (β [95% CI]) of fetal overnutrition (obesity and GDM, obesity only, and GDM only) with metabolite factor scores across 6 years of follow-up among 444 youth in the EPOCH cohort.

| Factor                   | Adjusted          | Adjusted          | Adjusted          |
|--------------------------|-------------------|-------------------|-------------------|
| γ-glutamyl               | −0.20 (−0.50, 0.10) | −0.14 (−0.44, 0.17) | −0.06 (−0.32, 0.20) |
| Sphingomyelin-mannose    | 0.29 (−0.04, 0.63) | −0.03 (−0.38, 0.33) | 0.32 (0.07, 0.57) * |
| Skeletal muscle metabolism | 0.36 (0.09, 0.64) * | 0.47 (0.21, 0.72) * | −0.10 (−0.34, 0.13) |
| CMPF                     | 0.50 (0.11, 0.89) * | 0.05 (−0.34, 0.44) | 0.45 (0.17, 0.73) * |

Adjusted model includes maternal smoking in pregnancy, child sex, race, and age at visit. Abbreviations: CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid; GDM, Gestational Diabetes Mellitus OB, pre-pregnancy obesity. * p < 0.05.

We found that the other three factors did differ by type of fetal overnutrition in both unadjusted (Figure 1) and adjusted models (Table 4). The sphingomyelin-mannose factor score, which had a similar top loading metabolite composition at each visit despite a difference in factor order, was higher among offspring of women with obesity only vs. GDM only. The skeletal muscle metabolism factor score was higher among offspring of women with obesity and GDM vs. GDM only or obesity only. The CMPF factor score was higher among offspring of women with obesity and GDM or obesity only vs. GDM only. The associations of fetal overnutrition typology with key metabolites (i.e., factor loading > 0.40) within each of these factors are shown in Supplementary Table S1. In general, the direction and significance of associations with key metabolites are similar but smaller in magnitude to those of the overall metabolite factors.

Sensitivity Analyses

After excluding women with type-one diabetes, the estimates with GDM only as the reference were attenuated, but with no impact on statistical significance. After adjustment for offspring BMI (a potential mediator to the relationship between fetal overnutrition and later-life metabolite profiles), the difference in the sphingomyelin-mannose factor scores between offspring of women with obesity only vs. GDM only was attenuated to null (Supplementary Table S2). No other associations were impacted by adjustment for offspring BMI. There were minimal changes in the significance of findings after adjusting for offspring Tanner stage, kilocalories, physical activity, or birthweight-for-gestational-age z-score (Supplementary Table S2). Adjusting for GDM treatment modality had minimal impact on the magnitude of association and significance, with the greatest impact (6% reduction in beta) observed for differences in the skeletal muscle metabolism factor between obesity and GDM vs. obesity only. There was no statistical evidence that the association between fetal overnutrition and metabolite profiles/factors scores were different in males versus females (all p-values for interaction terms >0.1).

2.4. Correlation of Offspring Metabolite Profiles and Indicators of Metabolic Health

Pearson correlations of the four metabolite factors of interest with conventional metabolic biomarkers and body composition are shown in Figure 2. In general, a higher score for the γ-glutamyl-peptide factor correlated with lower measures of adiposity, higher total cholesterol, and greater physical activity. The sphingomyelin-mannose factor was strongly positively correlated with adiposity and lipids (high-density lipoprotein, low-density lipo-protein, cholesterol). The skeletal muscle metabolism factor was positively correlated with adiposity and insulin resistance, and inversely correlated with lipids. The CMPF factor showed weak to no correlations with offspring indicators of metabolic health.
overnutrition and metabolite profiles/factors scores were different in males versus females (all $p$-values for interaction terms $>0.1$).

2.4. Correlation of Offspring Metabolite Profiles and Indicators of Metabolic Health

Pearson correlations of the four metabolite factors of interest with conventional metabolic biomarkers and body composition are shown in Figure 2. In general, a higher score for the $\gamma$-glutamyl-peptide factor correlated with lower measures of adiposity, higher total cholesterol, and greater physical activity. The sphingomyelin-mannose factor was strongly positively correlated with adiposity and lipids (high-density lipoprotein, low-density lipoprotein, cholesterol). The skeletal muscle metabolism factor was positively correlated with adiposity and insulin resistance, and inversely correlated with lipids. The CMPF factor showed weak to no correlations with offspring indicators of metabolic health.

Figure 2. Pearson correlation of offspring clinical metabolic and body composition markers and metabolomic factors at the childhood and adolescent visits. * $p<0.05$. (A) Correlations at ~10 years of age. (B) Correlations at ~16 years of age. Abbreviations: CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid; SM, sphingomyelins.

3. Discussion

3.1. Summary of Overall Findings

In this longitudinal study of 440 mother–offspring pairs, we sought to identify sustained differences in serum metabolites across childhood and adolescence among youth exposed to fetal overnutrition, and explored differences in metabolite profiles with respect to typology of fetal overnutrition (obesity only, GDM only, obesity and GDM). Exposure to any fetal overnutrition was associated with persistent metabolic changes in the offspring, but further differences between typologies of overnutrition account for a relatively small amount of variation in the metabolome, suggesting that there is likely a greater degree of pathophysiological overlap than distinct differences.
3.2. γ-Glutamyl Peptides Factor

The greatest amount of variation in metabolites associated with developmental overnutrition was accounted for by the γ-glutamyl-peptide factor, although this factor did not differ by overnutrition typology after adjustment for confounders. Key metabolites in this factor were derivates of glutamate (non-essential amino acid), lysine (essential amino acid), and glycine (gluconeogenic amino acid). GDM has been associated with a higher glutamine/glutamate ratio in cord blood [10] and glutamine has been associated with amino acid-mediated insulin secretion, and is sensitive to dietary changes [15–17]. Thus, this latter finding in cord blood may reflect both offspring’s exposure to hyperglycemia and the dietary and lifestyle changes implemented by women with GDM, which are also likely adopted by their children.

Methionine sulfoxide was also a top loading metabolite in the γ-glutamyl-peptide factor. This amino acid metabolite is a resulting compound of oxidation by reactive oxygen species that influences redox homeostasis and regulates many metabolic pathways including protein synthesis [18]. In mice with diet-induced obesity, deletion of enzymes required for reduction of methionine sulfoxide resulted in diminished insulin receptor function [19], highlighting a potential role of protein oxidation in insulin signaling. Thus, this component of the γ-glutamyl-peptide factor may represent differences in oxidative stress associated with fetal overnutrition.

Interestingly, we found that the correlation of the γ-glutamyl-peptide factor with indicators of metabolic health in offspring was in a direction indicative of a more favorable metabolic profile—lower adiposity, increased insulin sensitivity, and greater physical activity. In children, plasma levels of glutamine, a precursor to glutamate, were higher following a reduction in BMI [15]. Indeed, our finding that γ-glutamyl-peptide factor metabolites were associated with both exposure to overnutrition and a more favorable metabolic profile in offspring may simply reflect the precursor–product relationship of glutamine and glutamate, and that some of these youth adopted healthier behaviors.

3.3. Sphingomyelin-Mannose Factor

Although there was no unifying theme among the metabolites in this factor, subclasses of metabolites in this pattern have been linked to obesity and metabolic risk [20–22]. Sphingomyelins and dihydrosphongomyelin are important constituents of plasma membranes that interact closely with cholesterol and directly impact cholesterol homeostasis [23]. Indeed, we found that the sphingomyelin-mannose factor was more strongly correlated with cholesterol in childhood and adolescence compared to any other factor. We found a higher sphingomyelin-mannose factor score among offspring of women with obesity only vs. GDM only, which was likely driven by offspring adiposity, as the estimate was attenuated after adjusting for offspring BMI [15]. Indeed, our finding that γ-glutamyl-peptide factor metabolites were associated with both exposure to overnutrition and a more favorable metabolic profile in offspring may simply reflect the precursor–product relationship of glutamine and glutamate, and that some of these youth adopted healthier behaviors.

Interpretation of our findings with this factor in the context of previous studies is somewhat difficult given that prior studies have used different indicators of fetal overnutrition (maternal weight gain, BMI, glucose levels, GDM), and metabolite profile composition and choice of targeted assays has been study-specific. In a pre-birth cohort of 330 mother–offspring pairs with metabolomics measured in childhood (5–7 years of age), a metabolite profile characterized by phosphatidylcholines, plasmalogens, sphingomyelins and some ceramides was positively correlated with maternal pregnancy weight gain, but negatively correlated with fasting glucose [8]. These findings remained significant following adjustment for maternal waist circumference—a marker of central adiposity. However, among 412 mother–offspring pairs, GDM was positively associated with cord blood metabolites from sub-classes of phosphatidylcholines and sphingomyelins, but these differences were no longer significant after adjusting for maternal BMI [24]. Taken together, the associations of fetal overnutrition with phospholipids and sphingomyelins in offspring may represent pathways of adiposity and glycemia that are distinct and specific to the lipid class, as well as overlapping, and which operate through shared maternal–offspring risk of obesity.
3.4. Skeletal Muscle Metabolism Factor

Key compounds in this factor included α-hydroxyisocaproate and 2-hydroxy-3-methylvalerate, ketoacid metabolites of the branched-chain amino acids (BCAA) leucine and isoleucine; malate and citrate, TCA cycle intermediaries [25]; and urate, a catabolite of purine metabolism [26]. Skeletal muscle metabolism of BCAAs is critical for maintaining energy homeostasis, as well as anaplerotic supply to the TCA cycle. In the current study, we found that exposure to any fetal overnutrition was associated with a higher score for this factor, especially among those exposed to obesity and GDM compared to either typology alone. Further, in both childhood and adolescence, the skeletal muscle metabolism factor was correlated with greater adiposity and HOMA-IR. In general, maternal BMI/obesity has been positively associated with cord blood BCAAs and their metabolites [7,10,11], which in turn, have been positively related to birthweight [7,11]. These data point toward the early origins of the relationship between obesity, BCAA catabolism, and insulin resistance, which has been repeatedly found in animal and adult populations [27–30].

3.5. CMPF Factor

CMPF and its hydroxylated metabolite hydroxy-CMPF are metabolites of furan and long-chain omega-3 fatty acids [31,32]. Although data have linked CMPF to diabetes and β-cell dysfunction, this finding was attributed to differences in dietary intake and not directly implicated in glucose metabolism [33,34]. We found that offspring of women with obesity and GDM or obesity only had higher CMPF factor scores compared to offspring exposed to GDM only, suggesting an association specific to maternal obesity. However, the CMPF factor accounted for only 3–4% of the variation in the metabolites associated with any developmental overnutrition and was not strongly correlated with conventional indicators of metabolic health in offspring. To our knowledge, prior studies in youth have not identified associations of maternal glucose or adiposity with CMPF. Thus, in the context of fetal overnutrition, the relevance of the differences in the CMPF factor requires further investigation.

3.6. Strengths and Limitations

Our study has several strengths. First, the repeated metabolomics data are a unique asset of the EPOCH cohort that allowed us to examine the association of fetal overnutrition across two sensitive life stages for development of metabolic disease risk: childhood and adolescence [6]. Assessment of sustained differences in metabolite profiles across these life stages has important implications for chronic disease etiology, which typically take root during the first decade of life [35,36], can be tracked across development [37], and eventually manifest as overt chronic disease in adulthood [38]. Second, we used a multi-step analytical approach that identified individual metabolites, as well as correlated metabolites depicted by a data-driven latent construct, enabling us to capture the biochemical interactions among compounds on the same and/or related metabolic pathways.

Limitations include only having data on GDM diagnosis (yes/no) and pre-pregnancy BMI, without further detail on specifics of maternal glycemic physiology (e.g., insulin secretion, insulin resistance). This may have contributed to the minimal differences in fetal overnutrition typology detected, as these features have been related to specific differences in neonatal outcomes [39]. Although we had a relatively large sample size of offspring (n = 440), especially in comparison to other metabolomics analyses of intrauterine exposures and outcomes in youth (n for most <350) [40,41], some fetal overnutrition-exposure groups were relatively small (e.g., obesity and GDM), which may have impacted our power to detect specific contrasts with this group. It is also worth noting that the PCA was implemented separately for the childhood and adolescence metabolite data. Thus, while the composition of top-loading metabolites for the factors of interest were similar, the weighting scheme for the factor loadings differed slightly between time points, potentially hindering direct comparability of factors across the follow-up. However, this approach is widely used in nutritional epidemiology to identify distinct dietary patterns.
both longitudinally within the same population, as well as for comparability purposes across populations [42–44]. Future longitudinal studies with complex matrix-variate data, similar to repeated measures of high-dimensional data, might consider the use of novel two-way principal component methods [45]. Although the current study was hypothesis-generating, it is worthwhile to note that the concurrent measurement of conventional metabolic biomarkers and metabolomics hinders directionality and makes any inference on causal mechanisms challenging. Finally, given the large number of metabolites used in the MWAS approach, we cannot discount the potential for false-positive findings, though we applied an (FDR) correction and implemented dimension reduction to reduce this possibility.

3.7. Conclusion and Future Direction

In this study of 444 mother–child pairs, fetal overnutrition, defined as in utero exposure to maternal obesity, GDM or both, was associated with differences in fasting serum concentrations of 52 metabolites in offspring across childhood and adolescence after FDR correction. Further assessment of differences in metabolite profiles within typology of fetal overnutrition revealed differences in sphingomyelin-mannose, skeletal muscle metabolism, and CMPF metabolite profiles. However, these differences accounted for a relatively small percent of variation in the metabolomics dataset, suggesting that although maternal obesity and GDM are often regarded as distinct conditions, their impact on the offspring metabolome does not differ greatly. Thus, studies investigating the impacts of obesity and GDM on offspring metabolite profiles may consider maternal obesity and GDM not as separate entities, but rather as degrees of severity within a metabolic spectrum. The metabolite factors in this study were correlated with established indicators of adiposity and metabolic risk in offspring, and thus, may capture some of the underlying metabolic dysregulation and chronic disease risk associated with fetal overnutrition [3–5]. Given the growing evidence that fetal overnutrition has impacts on offspring health across the life span, future research is warranted to identify whether etiologic pathways, mechanisms, and mediators linking fetal overnutrition to the metabolic differences found herein are relevant to overt disease states.

4. Materials and Methods

4.1. Study Population

This hypothesis-generating analysis included mother–offspring pairs from the Exploring Perinatal Outcomes among Children (EPOCH) cohort. Eligible participants were children exposed to maternal GDM and a random sample of children not exposed and without intrauterine growth restriction (defined as birthweight-for-gestational-age score <the 10th percentile) (n = 604). Eligibility criteria for EPOCH were offspring of singleton pregnancies delivered between 1992 and 2002 whose biological mothers were members of the Kaiser Permanente of Colorado Health Plan. Details on recruitment and study population have been previously published [46]. In 2006–2009 and 2012–2015, offspring were invited to complete two research visits: first in childhood between 6 and 14 years old (mean age, 10.4 ± 1.5 years) and second in adolescence between 12 and 19 years old (mean age, 16.7 ± 1.2 years). From here forward, these visits are referred to as the childhood and adolescent visits, respectively. At both research visits, fasting blood was collected, refrigerated immediately, processed within 24 h, and stored at −80 °C until the time of analysis. These samples were used for untargeted metabolomics profiling and conventional biomarker assays.

For the current analysis, we excluded women missing data on pre-pregnancy BMI (n = 161), followed by offspring without sufficient blood volume for untargeted metabolomics profiling (n = 3). The analytic sample for this study included 440 mother–offspring pairs. In comparison to the 160 offspring who were not included in this analysis, the present sample was slightly younger and had a lower proportion of females, lower proportion of non-Hispanic white, and higher proportion of Hispanic youth.
4.2. Assessment of Exposure to Fetal Overnutrition

4.2.1. Gestational Diabetes Mellitus

Women were screened for GDM based on the National Diabetes Data Group, which follows a two-step approach [47]. Presence of a GDM diagnosis was abstracted from medical records.

4.2.2. Obesity

Maternal pre-pregnancy BMI (kg/m²) was calculated from pre-pregnancy weight abstracted from the medical records and height measured at the childhood visit. Obesity was defined as a pre-pregnancy BMI ≥ 30.0 kg/m².

4.2.3. Typology of Fetal Overnutrition

We assessed three typologies of fetal overnutrition: resulting from both maternal obesity and GDM (n = 25), maternal obesity only (n = 66), and GDM only (n = 56). Offspring of women without obesity or GDM were the reference group (n = 297).

4.3. Assessment of Metabolite Profiles in Offspring

Details on the untargeted metabolomic profiling in the EPOCH cohort have been published [9,48]. Briefly, Metabolon © (Morrisville, NC, USA) carried out untargeted metabolomics from the fasting serum collected at the childhood and adolescent visits using a multi-platform mass spectroscopy (MS)-based technique. Serum samples from both visits were analyzed at the same time, resulting in balanced batches and increased comparability of relative metabolite concentrations across both time points. Prior to formal statistical analysis, we removed metabolites with ≥20% missing values and imputed metabolites with <20% missing using the k-nearest neighbor technique (k = 10). There were 766 metabolites identified in both batches from the childhood and adolescent visit. Metabolite levels were log10-transformed, normalized, and corrected for batch effects (as well as other biological and technical variability) using the remove-unwanted-variation method (the number of factors of unwanted variation estimated from the data [k] = 2). In this analysis, we retained 637 metabolites at both the childhood and adolescent visit that were annotated. All metabolite processing was performed using R (Version 3.5.3; Vienna, Austria).

4.4. Assessment of Conventional Biomarkers of Metabolic Risk in Offspring

4.4.1. Biomarkers

Fasting triglycerides (TGs), total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and glucose were measured using enzymatic kits. Insulin was measured using a radioimmune assay, and leptin and adiponectin were measured using a Multiplex assay kit, all by Millipore Corporation (Darmstadt, Germany). We calculated the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). At both research visits, research assistants measured offspring’ blood pressure twice in the sitting position using an oscillometric monitor (Dinamap ProCare V100).

4.4.2. Anthropometric and Body Composition

At each research visit, offspring waist circumference, triceps and subscapular skinfold thickness, height, and weight were measured. BMI was calculated as kg/m², age- and sex-specific BMI z-scores were derived using the World Health Organization (WHO) growth reference for children aged 5–19 years [49], and the mean of triceps and subscapular skinfolds were summed. MRI of the abdominal region was used to quantify visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) depots with a 3 T HDx Imager (General Electric, Waukashau, WI, USA) by a trained technician. One axial, 10 mm, T1-weighted image, at the umbilicus or L4/L5 vertebrae, was analyzed to determine SAT and VAT content by a single reader, blinded to exposure status.
4.4.3. Lifestyle Behaviors

At each research visit, total energy intake (calories/day) was assessed using the Block Kid’s Food Questionnaire [50]. Average energy expenditure was calculated based on number of minutes of moderate-to-vigorous activity per day based on a 3-day self-report physical activity questionnaire [51].

4.5. Covariates

Maternal level of education, total household income, and smoking at any time during pregnancy were self-reported during the childhood visit. Offspring race and ethnicity, sex, and date of birth were self-reported at the first research visit.

4.6. Statistical Analysis

We assessed bivariate associations of maternal and offspring characteristics with typology of fetal overnutrition and tested for statistical differences using an ANOVA for continuous variables and Pearson chi-squared tests for categorical variables. This step, in conjunction with prior knowledge of determinants of metabolic health in youth, informed covariate selection for multivariable analysis. We then conducted the analysis in three sequential steps outlined below.

4.6.1. Identification of Offspring Metabolites Associated with Any Fetal Overnutrition

We implemented a metabolome-wide association study (MWAS) using linear mixed models to identify offspring metabolites across the childhood and adolescent visits that were persistently associated with exposure to any type of fetal overnutrition.

\[
Y_{ij} = \beta_1 x_{1i} + \beta_2 x_{2i} + X_3 \beta_3 + x_4 \beta_4 + \epsilon_{ij}
\]

where \(Y\) is the metabolite for individual \(i\) at time \(j\). \(x_1 = \) intercept; \(x_2 = \) fetal overnutrition category (maternal obesity or GDM vs. neither); \(X_3 = \) a vector of time-invariant factors (maternal smoking, offspring sex, ethnicity and race); \(x_4 = \) offspring age for individual \(i\) at time \(j\); \(\epsilon = \) error term \(i\) at time \(j\).

For these models, the outcome (\(Y\)) is repeated assessments of the metabolites for individual \(i\) at time \(j\) (childhood and adolescent visits), \(\beta\)'s are the main independent variable/exposure of interest (fetal overnutrition: maternal obesity or GDM vs. neither), and covariates (maternal smoking during pregnancy, offspring sex, and ethnicity and race, and offspring age for individual \(i\) at time \(j\)). We included offspring ID as a repeated subject statement to account for correlation between metabolites from the same individual with an unstructured correlation matrix. Considering the number of tests and high degree of correlation among metabolites, we employed a FDR described by Benjamini and Hochberg (1995) at level \(\alpha = 0.20\) [52].

4.6.2. Associations of Fetal Overnutrition Typology with Offspring Metabolite Profiles

First, we consolidated the metabolites from Step 1 into distinct metabolite profiles using principal component analysis (PCA), an unsupervised dimension-reduction approach that creates latent variables (i.e., metabolite profiles) based on their intercorrelations. This procedure, completed separately for metabolite data at the childhood and adolescent visit, reduced the number of subsequent comparisons and enhanced interpretability given that metabolites on related metabolic pathways are correlated with one another. Upon creation of the PCA factors, we determined the number of factors to retain at each visit based on visual inspection of the Scree plots. To interpret the factors, we assessed the composition of each factor and focused on metabolites with positive factor loadings \(\geq 0.40\).

When assessing the composition of each factor at the childhood and adolescent visits, we found that despite slight differences in the factor order—an indicator of the amount of variation explained by each factor—there were factors with the same combination of high-loading metabolites at both visits. For instance, the high-loading metabolites of the
first factor at the childhood and adolescent visit were the same, as was the case for high-loading metabolites of the third factor at the childhood visit and the second factor of the adolescent visit, despite slight variation in the exact degree of loading. These factors, for which metabolite composition was similar across the two visits, were of interest as they represent persistent metabolic differences in the offspring’s metabolite profile that spanned both time points.

We then used linear mixed models to examine associations of fetal overnutrition typology with the metabolite factors across the childhood and adolescent visits. In the models, fetal overnutrition was categorized as a four-level parameter: obesity and GDM, obesity only, GDM only, and neither obesity nor GDM (reference) and repeated metabolite factors were the outcome. We used contrast statements to compare the difference in our response variable (metabolite factors) between different levels of the fetal overnutrition parameter. This allows us to compare the difference in metabolite factor between all three different combinations of our fetal overnutrition parameter. The contrasts used the following specification: (1) obesity and GDM vs. GDM only, (2) obesity and GDM vs. obesity only, and (3) obesity only vs. GDM. If a factor was associated with a specific fetal overnutrition typology, we then further explored differences in individual metabolites from that factor. We assessed unadjusted associations followed by adjusted associations after accounting for maternal prenatal smoking, and offspring sex, age, and ethnicity and race.

The following sensitivity analyses were conducted. Seven women in the GDM-only typology had type-one diabetes; we excluded them in multivariable models to assess if potential etiological differences of hyperglycemia in pregnancy impacted the conclusions. Second, although birthweight, BMI, kilocalories, and physical activity are potential mediators to the relationship between fetal overnutrition and metabolite profiles during childhood and adolescence, we assessed the impact of including birthweight-for-gestational-age z-score, and repeated measures of BMI, kilocalories, and physical activity in separate multivariable models. Third, in multivariable models we additionally adjusted for Tanner stage at the childhood and adolescent visits. Fourth, we assessed the impact of adjustment for GDM treatment in the multivariable models. Lastly, we tested for an interaction with offspring sex in unadjusted models to assess for evidence that the association between fetal overnutrition and metabolite profiles/factors scores was different in males versus females.

4.6.3. Correlation of Offspring Metabolite Profiles and Indicators of Metabolic Health and Lifestyle

We used Pearson correlation coefficients to inform interpretation of offspring metabolite profiles captured by the factors and their correlation to concurrently measured conventional indicators of metabolic health (conventional metabolic biomarkers, anthropometry, and lifestyle). Statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA).

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/metabo12030265/s1, Table S1: Longitudinal associations (β [95% CI]) of fetal overnutrition (obesity and GDM, obesity only, and GDM only) with top loading metabolites across 6 years of follow-up among 444 youth in the EPOCH cohort, Table S2: Adjusted longitudinal associations (β [95% CI]) of fetal overnutrition (obesity and GDM, obesity only, and GDM only) with metabolite factor scores across 6 years of follow-up among 444 youth in the EPOCH cohort.

Author Contributions: E.C.F. and W.P. designed research question; E.C.F. analyzed data with critical oversight by W.P. and K.K.; E.C.F., K.K., C.C.C., D.D., and W.P. wrote the paper; G.M. provided insight into metabolite factors. E.C.F. and W.P. had primary responsibility for final content. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Institutes of Health (NIH), National Institute of Diabetes, Digestive, and Kidney Diseases (R01 DK068001). Francis is supported by NICHD grant no. 1K99HD108272-01. Cohen is supported by NIDDK grant no. T32DK07658. Perng is supported by a CCTSI KL2-TR002534 award.
Institutional Review Board Statement: The study was approved by Colorado Multiple Institutional Review Board (809-0563). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed Consent Statement: Mothers provided written informed consent and children provided written assent.

Data Availability Statement: Data Availability Statement: Because of the participant consent obtained as part of the recruitment process, it is not possible to make these data publicly available. The data resented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Perng, W.; Oken, E.; Dabelea, D. Developmental overnutrition and obesity and type 2 diabetes in offspring. Diabetologia 2019, 62, 1779–1788. [CrossRef] [PubMed]

2. Kim, S.Y.; England, L.; Wilson, H.G.; Bish, C.; Satten, G.A.; Dietz, P. Percentage of gestational diabetes mellitus attributable to overweight and obesity. Am. J. Public Health 2010, 100, 1047–1052. [CrossRef]

3. Clausen, T.D.; Mathiesen, E.R.; Hansen, T.; Pedersen, O.; Jensen, D.M.; Laubenborg, J.; Damm, P. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes. Diabetes Care 2008, 31, 340. [CrossRef] [PubMed]

4. Lowe, W.L., Jr.; Scholtens, D.M.; Lowe, L.P.; Kuang, A.; Nodzenski, M.; Talbot, O.; Catalano, P.M.; Linder, B.; Brickman, W.J.; Clayton, P.; et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA 2018, 320, 1005–1016. [CrossRef] [PubMed]

5. Razaz, N.; Villamor, E.; Muraca, G.M.; Bonamy, A.-K.E.; Cnattingius, S. Maternal obesity and risk of cardiovascular diseases in offspring: A population-based cohort and sibling-controlled study. Lancet Diabetes Endocrinol. 2020, 8, 572–581. [CrossRef]

6. Hivert, M.F.; Perng, W.; Watkins, S.M.; Newgard, C.S.; Kenny, L.C.; Kristal, B.S.; Patti, M.E.; Isganaitis, E.; DeMeo, D.L.; Oken, E.; et al. Metabolomics in the developmental origins of obesity and its cardiometabolic consequences. J. Dev. Orig. Health Dis. 2015, 6, 65–78. [CrossRef] [PubMed]

7. Lowe, W.L., Jr.; Bain, J.R.; Nodzenski, M.; Reisetter, A.C.; Muehlbauer, M.J.; Stevens, R.D.; Ilkayeva, O.R.; Lowe, L.P.; Metzger, B.E.; Newgard, C.B.; et al. Maternal BMI and glycemia impact the fetal metabolome. Diabetes Care 2017, 40, 902–910. [CrossRef] [PubMed]

8. Rahman, M.L.; Doyon, M.; Arguin, M.; Perron, P.; Bouchard, L.; Hivert, M.-F. A prospective study of maternal adiposity and glycemic traits across pregnancy and mid-childhood metabolic profiles. Int. J. Obes. 2021, 45, 860–869. [CrossRef]

9. Perng, W.; Ringham, B.M.; Smith, H.A.; Michelotti, G.; Kechriss, K.M.; Dabelea, D. A prospective study of associations between in utero exposure to gestational diabetes mellitus and metabolomic profiles during late childhood and adolescence. Diabetologia 2020, 63, 296–312. [CrossRef]

10. Shokry, E.; Marchioro, L.; Uhl, O.; Bermudez, M.G.; Garcia-Santos, J.A.; Segura, M.T.; Campoy, C.; Koletzko, B. Impact of maternal BMI and gestational diabetes mellitus on maternal and cord blood metabolome: Results from the PREOBE cohort study. Acta Diabetol. 2019, 56, 421–430. [CrossRef]

11. Perng, W.; Rifas-Shiman, S.L.; McCulloch, S.; Chatzi, L.; Mantzoros, C.; Hivert, M.F.; Oken, E. Associations of cord blood metabolites with perinatal characteristics, newborn anthropometry, and cord blood hormones in project viva. Metabolism 2017, 76, 11–22. [CrossRef]

12. Barbou, L.A.; McCurdy, C.E.; Hernandez, T.L.; Kirwan, J.P.; Catalano, P.M.; Friedman, J.E. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 2007, 30, S112. [CrossRef] [PubMed]

13. Oken, E.; Kleinman, K.P.; Rich-Edwards, J.; Gillman, M.W. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatrics 2003, 3, 6. [CrossRef] [PubMed]

14. World Health Organization (WHO). Available online: https://www.BMI-for-AgeandSex(5--19Years) (accessed on 5 February 2021).

15. Reinehr, T.; Wolters, B.; Knop, C.; Lass, N.; Hellmuth, C.; Harder, U.; Peissner, W.; Wahl, S.; Grallert, H.; Adamski, J.; et al. Changes in the serum metabolite profile in obese children with weight loss. Eur. J. Nutr. 2015, 54, 173–181. [CrossRef] [PubMed]

16. MacDonald, M.J.; Fahien, L.A.; Brown, L.I.; Hasan, N.M.; Buss, J.D.; Kendrick, M.A. Perspective: Emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion. Am. J. Physiol.-Endocrinol. Metab. 2005, 288, E1–E15. [CrossRef] [PubMed]

17. Brunengraber, H.; Roe, C.R. Anaplerotic molecules: Current and future. J. Inherit. Metab. Dis. 2006, 29, 327–331. [CrossRef] [PubMed]

18. Lee, B.C.; Gladyshev, V.N. The biological significance of methionine sulfoxide stereochemistry. Free Radic. Biol. Med. 2011, 50, 221–227. [CrossRef]

19. Styskal, J.; Nwagwu, F.A.; Watkins, Y.N.; Liang, H.; Richardson, A.; Musi, N.; Salmon, A.B. Methionine sulfoxide reductase A affects insulin resistance by protecting insulin receptor function. Free Radic. Biol. Med. 2013, 56, 123–132. [CrossRef]
20. Boini, K.M.; Xia, M.; Koka, S.; Gehr, T.W.B.; Li, P.-L. Sphingolipids in obesity and related complications. Front. Biosci. 2017, 22, 96–116. [CrossRef]

21. Lee, S.; Zhang, C.; Kilicarslan, M.; Piening, B.D.; Björnsson, E.; Hallström, B.M.; Groen, A.K.; Ferrannini, E.; Laakso, M.; Snyder, M.; et al. Integrated network analysis reveals an association between plasma mannose levels and insulin resistance. Cell Metab. 2016, 24, 172–182. [CrossRef]

22. Samad, F.; Hester, K.D.; Yang, G.; Hannun, Y.A.; Bielawski, J. Altered adipose and plasma sphingolipid metabolism in obesity. Diabetes 2006, 55, 2579. [CrossRef] [PubMed]

23. Slote, J.P. Biological functions of sphingomyelins. Prog. Lipid Res. 2013, 52, 424–437. [CrossRef] [PubMed]

24. Lu, Y.P.; Reichetzeder, C.; Prehn, C.; von Websky, K.; Slowinski, T.; Chen, Y.P.; Yin, L.H.; Kleuser, B.; Yang, X.S.; Adamski, J.; et al. Fetal serum metabolites are independently associated with gestational diabetes mellitus. Cell Physiol. Biochem. 2018, 45, 625–638. [CrossRef] [PubMed]

25. Wang, J.; Liu, Y.; Lian, K.; Shentu, X.; Fang, J.; Shao, J.; Chen, M.; Wang, Y.; Zhou, M.; Sun, H. BCAA catabolic defect alters glucose metabolism in lean mice. Front. Physiol. 2019, 10, 1140. [CrossRef] [PubMed]

26. Maiuolo, J.; Oppedisano, F.; Gratteri, S.; Muscoli, C.; Mollace, V. Regulation of uric acid metabolism and excretion. Int. J. Cardiol. 2016, 213, 8–14. [CrossRef] [PubMed]

27. Lynch, C.J.; Adams, S.H. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat. Rev. Endocrinol. 2014, 10, 723–736. [CrossRef] [PubMed]

28. Wurtz, P.; Soininen, P.; Kangas, A.J.; Ronnemaa, T.; Lehtimaki, T.; Kahonen, M.; Viikari, J.S.; Raitakari, O.T.; Ala-Korpela, M. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 2013, 36, 648–655. [CrossRef] [PubMed]

29. Wang, T.J.; Larson, M.G.; Vasan, R.S.; Cheng, S.; McCabe, E.; Lewis, G.D.; Fox, C.S.; Jacques, P.F.; Fernandez, C.; et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011, 17, 448–453. [CrossRef] [PubMed]

30. Cheng, S.; Rhee, E.P.; Larson, M.G.; Lewis, G.D.; McCabe, E.L.; Shen, D.; Palma, M.J.; Roberts, L.D.; Dejam, A.; Souza, A.L.; et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012, 125, 2222–2231. [CrossRef] [PubMed]

31. Zheng, J.S.; Lin, M.; Imamura, F.; Cai, W.; Wang, L.; Feng, J.P.; Ruan, Y.; Tang, J.; Wang, F.; Yang, H.; et al. Serum metabolomics profiles in response to n-3 fatty acids in Chinese patients with type 2 diabetes: A double-blind randomised controlled trial. Sci. Rep. 2016, 6, 29522. [CrossRef] [PubMed]

32. Price, N.D.; Magis, A.T.; Earls, J.C.; Glusman, G.; Levy, R.; Lausted, C.; McDonald, D.T.; Kusebauch, U.; Moss, C.L.; Zhou, Y.; et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat. Biotechnol. 2017, 35, 747–756. [CrossRef]

33. Prentice, K.J.; Luu, L.; Allister, E.M.; Liu, Y.; Jun, L.S.; Sloop, K.W.; Hardy, A.B.; Wei, L.; Jia, W.; Fantus, I.G.; et al. The furan fatty acid metabolite CMPF is elevated in diabetes and induces beta cell dysfunction. Cell Metab. 2014, 19, 653–666. [CrossRef] [PubMed]

34. Larsson, S.; Härnsten, J.; Håkansson, L.; Winkel, P.; Wahl, J.; Persson, M.; Järve, P.; Rubin, K.; Wiman, K.; Hammar, E.; et al. Heterogeneous contribution of insulin sensitivity and secretion defects to gestational diabetes mellitus. Diabetes Care 2016, 39, 1052–1055. [CrossRef] [PubMed]

35. Perem, W.; Herting, E.C.; Song, P.X.K.; Tellez Rojo, M.M.; Raskind, S.; Kachman, M.; Cantoral, A.; Burant, C.F.; Peterson, K.E. Metabolic determinants of metabolic risk in mexican adolescents. Obesity 2017, 25, 1594–1602. [CrossRef]

36. Perem, W.; Oken, E.; Rounieliotaki, T.; Sood, D.; Siskos, A.P.; Chalkiadaki, G.; Dernitzaki, E.; Vafeiadis, M.; Kyrtopoulos, S.; Kogevas, M.; et al. Leptin, acylcarnitine metabolites and development of adiposity in the Rhea mother–child cohort in Crete, Greece. Obes. Sci. Pract. 2016, 2, 471–476. [CrossRef]

37. Batis, C.; Mendez, M.A.; Gordon-Larsen, P.; Sotres-Alvarez, D.; Adair, L.; Popkin, B. Using both principal component analysis and reduced rank regression to study dietary patterns and diabetes in Chinese adults. Public Health Nutr. 2016, 19, 195–203. [CrossRef]
44. Batis, C.; Mendez, M.A.; Sotres-Alvarez, D.; Gordon-Larsen, P.; Popkin, B. Dietary pattern trajectories during 15 years of follow-up and HbA1c, insulin resistance and diabetes prevalence among Chinese adults. *J. Epidemiol. Community Health* **2014**, *68*, 773–779. [CrossRef] [PubMed]

45. Huang, L.; Reiss, P.T.; Xiao, L.; Zipunnikov, V.; Lindquist, M.A.; Crainiceanu, C.M. Two-way principal component analysis for matrix-variate data, with an application to functional magnetic resonance imaging data. *Biostatistics* **2017**, *18*, 214–229. [CrossRef] [PubMed]

46. Crume, T.L.; Ogden, L.; West, N.A.; Vehik, K.S.; Scherzinger, A.; Daniels, S.; McDuffie, R.; Bischoff, K.; Hamman, R.F.; Norris, J.M.; et al. Association of exposure to diabetes in utero with adiposity and fat distribution in a multiethnic population of youth: The exploring perinatal outcomes among children (EPOCH) study. *Diabetologia* **2011**, *54*, 87–92. [CrossRef]

47. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. *Diabetes* *A J. Am. Diabetes Association.* **1979**, *28*, 1039–1057. [CrossRef]

48. Perng, W.; Francis, E.C.; Smith, H.A.; Carey, J.; Wang, D.; Kechris, K.M.; Dabelea, D. Sex-specific metabolite biomarkers of NAFLD in youth: A prospective study in the EPOCH cohort. *J. Clin. Endocrinol. Metab.* **2020**, *105*, e3437–e3450. [CrossRef]

49. De Onis, M.; Onyango, A.W.; Borghi, E.; Siyam, A.; Nishida, C.; Siekmann, J. Development of a WHO growth reference for school-aged children and adolescents. *Bull. World Health Organ.* **2007**, *85*, 660–667. [CrossRef] [PubMed]

50. Cullen, K.W.; Watson, K.; Zakeri, I. Relative reliability and validity of the block kids questionnaire among youth aged 10 to 17 Years. *J. Am. Diet. Assoc.* **2008**, *108*, 862–866. [CrossRef]

51. Weston, A.T.; Petosa, R.; Pate, R.R. Validation of an instrument for measurement of physical activity in youth. *Med. Sci. Sports Exerc.* **1997**, *29*, 138–143. [CrossRef]

52. Benjamini, Y.; Liu, W. A step-down multiple hypotheses testing procedure that controls the false discovery rate under independence. *J. Stat. Plan. Inference* **1999**, *82*, 163–170. [CrossRef]